These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33667688)

  • 21. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
    Dutta Gupta S; Bommaka MK; Banerjee A
    Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
    Miyata Y
    Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
    Chen X; Liu P; Wang Q; Li Y; Fu L; Fu H; Zhu J; Chen Z; Zhu W; Xie C; Lou L
    Cancer Lett; 2018 Oct; 434():70-80. PubMed ID: 30017966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer.
    Wang L; Jiang J; Zhang L; Zhang Q; Zhou J; Li L; Xu X; You Q
    J Med Chem; 2020 Feb; 63(3):1281-1297. PubMed ID: 31935086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plant-Based HSP90 Inhibitors in Breast Cancer Models: A Systematic Review.
    Zarguan I; Ghoul S; Belayachi L; Benjouad A
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation.
    Goode KM; Petrov DP; Vickman RE; Crist SA; Pascuzzi PE; Ratliff TL; Davisson VJ; Hazbun TR
    Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1992-2006. PubMed ID: 28495207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer.
    Wang L; Zhang L; Li L; Jiang J; Zheng Z; Shang J; Wang C; Chen W; Bao Q; Xu X; Jiang Z; Zhang J; You Q
    Sci Adv; 2019 Sep; 5(9):eaax2277. PubMed ID: 31555737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization.
    Allan RK; Mok D; Ward BK; Ratajczak T
    J Biol Chem; 2006 Mar; 281(11):7161-71. PubMed ID: 16421106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
    Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
    Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways.
    Xue N; Jin J; Liu D; Yan R; Zhang S; Yu X; Chen X
    Curr Cancer Drug Targets; 2014; 14(7):671-83. PubMed ID: 25219422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
    Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
    Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
    Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
    Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
    Bickel D; Gohlke H
    Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning.
    Smith JR; Workman P
    Cell Cycle; 2009 Feb; 8(3):362-72. PubMed ID: 19177013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
    Chandarlapaty S; Scaltriti M; Angelini P; Ye Q; Guzman M; Hudis CA; Norton L; Solit DB; Arribas J; Baselga J; Rosen N
    Oncogene; 2010 Jan; 29(3):325-34. PubMed ID: 19855434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dipyridamole interacts with the N-terminal domain of HSP90 and antagonizes the function of the chaperone in multiple cancer cell lines.
    Gao J; Zhou C; Zhong Y; Shi L; Luo X; Su H; Li M; Xu Y; Zhang N; Zhou H
    Biochem Pharmacol; 2023 Jan; 207():115376. PubMed ID: 36513142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of celastrol, a triterpene with antitumorigenic activity, on conformational and functional aspects of the human 90kDa heat shock protein Hsp90α, a chaperone implicated in the stabilization of the tumor phenotype.
    Zanphorlin LM; Alves FR; Ramos CH
    Biochim Biophys Acta; 2014 Oct; 1840(10):3145-52. PubMed ID: 24954307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects.
    Chan CT; Reeves RE; Geller R; Yaghoubi SS; Hoehne A; Solow-Cordero DE; Chiosis G; Massoud TF; Paulmurugan R; Gambhir SS
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2476-85. PubMed ID: 22895790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternative approaches to Hsp90 modulation for the treatment of cancer.
    Hall JA; Forsberg LK; Blagg BS
    Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function.
    Wang L; Li L; Gu K; Xu XL; Sun Y; You QD
    Curr Drug Targets; 2017; 18(13):1572-1585. PubMed ID: 27231111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.